307 related articles for article (PubMed ID: 16842153)
1. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
Neckers L
Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
[TBL] [Abstract][Full Text] [Related]
2. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
3. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
Neckers L
Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289
[TBL] [Abstract][Full Text] [Related]
5. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
Hadden MK; Lubbers DJ; Blagg BS
Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
[TBL] [Abstract][Full Text] [Related]
6. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
7. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.
Marcu MG; Schulte TW; Neckers L
J Natl Cancer Inst; 2000 Feb; 92(3):242-8. PubMed ID: 10655441
[TBL] [Abstract][Full Text] [Related]
8. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
Tsutsumi S; Neckers L
Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
[TBL] [Abstract][Full Text] [Related]
9. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
Neckers L; Neckers K
Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
[TBL] [Abstract][Full Text] [Related]
10. Chaperoning oncogenes: Hsp90 as a target of geldanamycin.
Neckers L
Handb Exp Pharmacol; 2006; (172):259-77. PubMed ID: 16610363
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90.
Neckers L; Ivy SP
Curr Opin Oncol; 2003 Nov; 15(6):419-24. PubMed ID: 14624223
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 is a rational molecular target in breast cancer.
Neckers L
Breast Dis; 2002; 15():53-60. PubMed ID: 15687645
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
15. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
Khandelwal A; Crowley VM; Blagg BSJ
Med Res Rev; 2016 Jan; 36(1):92-118. PubMed ID: 26010985
[TBL] [Abstract][Full Text] [Related]
16. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
Shen G; Wang M; Welch TR; Blagg BS
J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibitors identified from a library of novobiocin analogues.
Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS
J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253
[TBL] [Abstract][Full Text] [Related]
19. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
[TBL] [Abstract][Full Text] [Related]
20. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
Franke J; Eichner S; Zeilinger C; Kirschning A
Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
